当地时间2月4日,默沙东发布2024年年度业绩报告并宣布一项重要决定:公司旗下人乳头瘤病毒疫苗(HPV疫苗)佳达修从2月开始暂停向中国市场发货,至少持续到今年年中。 对于这一决定,默沙东方面回应《国际金融报》记者称,这是同本土合作伙伴智飞生物深入沟通的结果。 “受整体市场环境、消费者需求疲软及渠道库存高等因素影响,公司决定自2025年2月起根据消费者需求的动态变化,阶段性调整中国市场的发货节奏...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.